Purification of 68Ge/68Ga generator eluate from Fe(III) intended to improve specific radioactivity of 68Ga-based radiopharmaceuticals
AssigneeGe Healthcare Limited
InventorsBengt Langstrom, Irina Velikyan
Life of this patent
Estimating the term…
Abstract
The present invention provides a method of purifying 68Ge/68Ga generator produced 68Ga from Fe (III). The invention further relates to an automated system within an existing Gallea Synthia prototype that provides purification 68Ga from various cations and preconcentrations of 68Ga. In general, the present invention further depicts the use of an automated system for the production of 68Ga-radiolabelled PET tracers with high specific radioactivity and a kit for purifying 68Ge/68Ga generator produced 68Ga from Fe (III).
Claims5
A method of purifying 68Ga from Fe(III) in a 68Ga generator eluate which comprises:
- (i) eluting a 68Ge/68Ga generator column with 0.05-0.1 M aqueous hydrochloric acid to give an eluate containing 68Ga and Fe(III);
- (ii) treatment of the eluate solution from step (i) to:
- (a) reduce the Fe(III) therein to Fe(II);
- (b) acidify with 30% w/v hydrochloric acid to give [68GaCl4]− in the eluate solution;
- wherein steps (a) and (b) may optionally be carried out concurrently;
- (iii) passing the reduced eluate solution from step (ii) through an anion exchange column comprising HCO3− counterions, wherein the [68GaCl4]− is retained on the anion exchange column and the Fe(II) passes through the anion exchange column without retention;
- and
- (iv) passing deionized water through the anion exchange column from step (iii) to elute purified 68Ga, having Fe(II) and Fe(III) removed therefrom and wherein the purified 68Ga has a purity that is suitable for use in chemotherapy and radiotherapy.
A method of purifying 68Ga from Fe(III) in a 68Ga generator eluate which comprises:
- (i) eluting a 68Ge/68Ga generator column with 0.05-0.1 M aqueous hydrochloric acid to give an eluate containing 68Ga and Fe(III);
- (ii) treatment of the eluate solution from step (i) to:
- (a) reduce the Fe(III) therein to Fe(II);
- (b) acidify with 30% w/v hydrochloric acid to give [68GaCl4]− in the eluate solution;
- wherein steps (a) and (b) may optionally be carried out concurrently;
- (iii) passing the reduced eluate solution from step (ii) through an anion exchange column comprising HCO3− counterions, wherein the [68GaCl4]− is retained on the anion exchange column and the Fe(II) passes through the anion exchange column without retention;
- and
- (iv) passing deionized water through the anion exchange column from step (iii) to elute purified 68Ga, having Fe(II) and Fe(III) removed therefrom and wherein the purified 68Ga has a purity that is suitable for use in chemotherapy and radiotherapy;
- wherein the reduction of step (ii) is carried out using either:
- (a) a borohydride functionalized resin;
- (b) a redox active hydroquinone functionalized polyacryclic acid polymer;
- or
- (c) a redox active hydroquinone functionalized divinylbenzene polymer.
Dependencies are inferred from the claim text.